EIKN

Eikon Therapeutics

Fundamental data last updated:April 13, 2026

We may earn a commission from partner links. This content is for informational purposes only and is not financial advice. Information may be delayed or inaccurate.

company profile

SECTOR

Healthcare

industry

Biotechnology

Exchange

Nasdaq

County of HQ

United States

Next Earnings Date

06/29/26

Business Summary

Eikon Therapeutics operates as a biotechnology company focused on developing advanced therapeutics, monetizing its platform through drug discovery and development rather than diversified recurring revenue streams. Cash generation, when it occurs, comes from advancing drug candidates through clinical milestones that increase asset value, potentially leading to partnerships, licensing agreements, or commercialization. The moat in biotech typically lies in proprietary platforms, intellectual property, and the ability to repeatedly generate viable clinical candidates. If its 38.00% operating margin and 53.50% ROIC reflect scalable platform economics, the competitive advantage would stem from capital-efficient drug discovery rather than a single-product dependency.

 


Analyze EIKN on TradingView

VALUATION

P/E

-

Market Cap ($M USD)

$487

Forward P/E

-

PEG

-

PRICE TO SALES

-

PRICE TO BOOK

-

EV / EBITDA

-1.4

5-Year Average P/E

Free Cash Flow Yield

DCF Value

Graham Number

Price to FCF

EV to FCF

Earnings Yield

FCF Yield

DIVIDEND

Yield

-

Annual Payout

-

Payout Ratio

-

Consecutive Years of Dividend Growth

-

5-Year Dividend Growth Rate

-

Financial Health & Profitability

Earnings Per Share

-$6.18

Next Year EPS Growth Estimate

-$5.66

Next Year Revenue Growth Estimate

-

Return on Equity (ROE)

38.00%

FREE CASH FLOW

Operating Margin

-

Debt-to-Equity

-

Piotroski F-Score

-

Altman Z-Score

-3.3

Return on Invested Capital (ROIC)

53.50%

Current Ratio

6.3

Quick Ratio

Net Debt to EBITDA

Interest Coverage

Gross Profit margin

FCF PER SHARE

REVENUE PER SHARE

Analyze EIKN on TradingView

Gainseekers Quantitative Analysis

Summary

Eikon Therapeutics is a $487M Nasdaq-listed biotechnology company with negative EPS of -1.4 and an even deeper projected EPS of -$6.18 next year, meaning there is no earnings support for the current valuation. The absence of a P/E, Forward P/E, PEG, and Price/Sales multiple signals a business still structurally unprofitable, and the Altman Z-Score of -3.3 is an outright distress signal that cannot be ignored. Yes, operating margin shows 38.00% and ROIC is 53.50%, but against a backdrop of projected negative sales growth of -$5.66 and worsening earnings, those figures look disconnected from bottom-line durability. This is not a misunderstood compounder — it is a speculative biotech trading on future optionality while flashing real balance sheet risk.

AI Exposure / Tech Reliance

As a biotechnology company in the Healthcare sector, Eikon sits in an industry where AI-driven drug discovery and data-centric research are increasingly central to competitive advantage. The biotech model naturally benefits from computational modeling, automation, and high-throughput analytics. However, without visible revenue growth metrics, the market is still treating this as a development-stage platform rather than a scaled AI-enabled commercial engine.

The Bull Case

A GARP-oriented investor willing to stomach volatility could argue that a 53.50% ROIC and a 38.00% operating margin are extraordinary for a company with a $487M market cap, particularly in biotech where capital is routinely destroyed. The current ratio of 6.3 implies substantial short-term liquidity, reducing immediate financing pressure and giving management runway into the 06/29/26 earnings cycle. Institutional ownership at $25.60 suggests that professional capital is involved, which can provide stability and validation. If those margins and capital returns are sustainable and not accounting artifacts, the market could be severely underestimating the embedded economics of its underlying platform.

The Bear Case

The bear case is far more concrete: EPS is -1.4 and expected to deteriorate to -$6.18 next year, while sales growth is projected at -$5.66 — a brutal forward trajectory. The Altman Z-Score of -3.3 places the company firmly in financial distress territory, and the absence of Debt/Equity, PEG, and valuation multiples removes any framework to justify paying for growth. There is no dividend, no yield, no payout, and no visible earnings inflection. In short, this is a cash-consuming biotech with worsening fundamentals trading primarily on narrative rather than demonstrated financial momentum.

Market Sentiment & Smart Money

Short Interest %

5.10%

Analyst Consensus

1.86

Average Analyst Price Target

$25.60

Institutional Ownership %

30.60%

1-Year Beta

2.34

Insider Buying % (6 Mo)

14.80%%

Distance to 52-Week High

51.70%

Distance to 52-Week Low

104.90%

EARNINGS SURPRISE %

50-DAY SMA

200-DAY SMA

⚠️ Financial Disclaimer:
This content is for informational purposes only and is not financial advice. Information may be delayed or inaccurate. We may earn a commission from partner links.